Form 8-K - Current report:
SEC Accession No. 0001683168-25-000357
Filing Date
2025-01-15
Accepted
2025-01-15 08:30:09
Documents
17
Period of Report
2025-01-13
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT sunshine_8k.htm   iXBRL 8-K 30481
2 EMPLOYMENT AGREEMENT sunshine_ex1001.htm EX-10.1 41289
3 PRESS RELEASE ANNOUNCING THE APPOINTMENT OF MR. MICHEL ROY AS CHIEF COMMERCIAL O sunshine_ex9901.htm EX-99.1 11591
4 GRAPHIC image_003.jpg GRAPHIC 6358
  Complete submission text file 0001683168-25-000357.txt   324402

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE sbfm-20240113.xsd EX-101.SCH 3553
6 XBRL DEFINITION FILE sbfm-20240113_def.xml EX-101.DEF 26585
7 XBRL LABEL FILE sbfm-20240113_lab.xml EX-101.LAB 36550
8 XBRL PRESENTATION FILE sbfm-20240113_pre.xml EX-101.PRE 25209
19 EXTRACTED XBRL INSTANCE DOCUMENT sunshine_8k_htm.xml XML 5521
Mailing Address 333 LAS OLAS WAY CU4 SUITE 433 FORT LAUDERDALE FL 33301
Business Address 333 LAS OLAS WAY CU4 SUITE 433 FORT LAUDERDALE FL 33301 954-515-0810
Sunshine Biopharma Inc. (Filer) CIK: 0001402328 (see all company filings)

EIN.: 205566275 | State of Incorp.: CO | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41282 | Film No.: 25531234
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)